OncoMatch/Clinical Trials/NCT05341557
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Is NCT05341557 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BPI-371153 for advanced solid tumor.
Treatment: BPI-371153 — A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-371153, a PD-L1 Inhibitor, in patients with advanced solid tumors or relapsed/refractory lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Non-Hodgkin Lymphoma
Non-Small Cell Lung Carcinoma
Hepatocellular Carcinoma
Disease stage
Required: Stage III, IV, RELAPSED
locally advanced or metastatic solid tumor; relapsed/refractory lymphoma; locally advanced or relapsed/metastatic Non-Driver Mutation NSCLC; HCC with Child-Pugh A or B(≤ 7 points)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
disease progression after standard therapy, intolerable to standard therapy, refuse to standard therapy or for whom no standard therapy exists
Cannot have received: immune checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-PD-L2)
Prior immune checkpoint inhibition with anti-programmed cell death-1 (PD1)/programmed death ligand-1(PD-L1) or programmed death ligand-2(PD-L2) therapy
Cannot have received: T cell targeting agent
Prior other specific T cell targeting agents
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
HCC with Child-Pugh A or B(≤ 7 points)
Adequate organ function; HCC with Child-Pugh A or B(≤ 7 points)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify